We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002601:SZSELB Group Co., Ltd. Class A Analysis

Data as of 2026-03-17 - not real-time

CN¥18.79

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

LB Group is trading at CNY 18.79, just above the computed support of 18.5 and well below its 52‑week high of 23.79, indicating limited upside in the immediate price range. The stock sits above its 20‑day SMA (21.21) and 50‑day SMA (20.89) but both averages remain above the current price, reflecting a still‑recovering bullish trend despite a bearish MACD histogram and signal. RSI at 34 suggests the shares are oversold, while a 30‑day volatility of 50% signals wide price swings. Fundamental metrics are mixed: a high trailing PE of 35.45 and a forward PE of 12.53 point to valuation pressure, while revenue has contracted 13.7% and margins are thin (gross 20.8%, operating 9%). The balance sheet is strained with a debt‑to‑equity of 95% and a payout ratio of 150%, making the 3.18% dividend unsustainable. Nonetheless, analysts rate the stock as a strong buy, with a median target of CNY 21.8 and mean target of CNY 23.0, implying roughly 20‑25% upside. The company benefits from a low‑beta profile (computed β 0.13) and stable trading volume, but high sector volatility and regulatory exposure in specialty chemicals add risk. Overall, the stock presents a classic value‑growth tension: attractive dividend yield and analyst optimism versus high leverage and modest profitability.
Investors should weigh the short‑term price pressure near support and bearish technical signals against the longer‑term upside potential embedded in analyst forecasts and the company’s strategic position in the titanium dioxide market. A cautious stance that monitors debt reduction progress and cash flow improvement is advisable.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support (18.5)
  • Bearish MACD and high short‑term volatility
  • Oversold RSI indicating potential rebound

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst consensus strong‑buy with 20%+ price upside
  • Forward earnings growth (EPS 1.5 vs 0.53 trailing)
  • Improving market sentiment (Extreme Greed index 81.5)

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic position in specialty chemicals and titanium dioxide
  • Potential debt deleveraging as cash flow stabilizes
  • Sustained dividend yield if payout ratio improves

Key Metrics & Analysis

Financial Health

Revenue Growth-13.70%
Profit Margin4.91%
P/E Ratio35.5
ROE5.19%
ROA2.47%
Debt/Equity95.28
P/B Ratio1.8
Op. Cash FlowCN¥3.7B
Free Cash FlowCN¥-3320164096

Technical Analysis

TrendBullish
RSI34.3
SupportCN¥18.50
ResistanceCN¥23.79
MA 20CN¥21.21
MA 50CN¥20.89
MA 200CN¥18.60
MACDBearish
VolumeStable
Fear & Greed Index81.48

Valuation

Fair ValueCN¥7.51
Target PriceCN¥23.03
Upside/Downside22.57%
GradeOvervalued
TypeBlend
Dividend Yield3.18%

Risk Assessment

Beta0.13
Volatility50.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.